Total Payments
$62,809
2024 Payments
$35,768
Companies
8
Transactions
54
Medicare Patients
798
Medicare Billing
$206,827
Payment Breakdown by Category
Consulting$36,755 (58.5%)
Research$24,705 (39.3%)
Food & Beverage$1,348 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $36,755 | 25 | 58.5% |
| Unspecified | $24,705 | 11 | 39.3% |
| Food and Beverage | $1,348 | 18 | 2.1% |
Payments by Type
General
$38,103
43 transactions
Research
$24,705
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| IGI Inc | $24,096 | 10 | $0 (2024) |
| GENZYME CORPORATION | $19,694 | 7 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $8,129 | 12 | $0 (2024) |
| Janssen Biotech, Inc. | $7,631 | 9 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,665 | 3 | $0 (2024) |
| Adaptive Biotechnologies Corporation | $772.87 | 11 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $609.30 | 1 | $0 (2023) |
| Karyopharm Therapeutics Inc. | $211.36 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35,768 | 28 | IGI Inc ($24,096) |
| 2023 | $12,359 | 17 | Janssen Biotech, Inc. ($6,250) |
| 2022 | $5,270 | 5 | GENZYME CORPORATION ($3,790) |
| 2021 | $9,181 | 2 | GENZYME CORPORATION ($9,181) |
| 2020 | $115.02 | 1 | Adaptive Biotechnologies Corporation ($115.02) |
| 2019 | $115.02 | 1 | Adaptive Biotechnologies Corporation ($115.02) |
All Payment Transactions
54 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | Janssen Scientific Affairs, LLC | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $89.57 | General |
| Category: Oncology | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| 11/19/2024 | Janssen Scientific Affairs, LLC | CARVYKTI (Drug) | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| Category: Oncology | ||||||
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| 10/11/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $58.81 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $54.00 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $45.00 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $73.34 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $68.76 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $58.89 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $46.66 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | Janssen Scientific Affairs, LLC | TALVEY (Biological) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 09/19/2024 | IGI Inc | — | — | Cash or cash equivalent | $1,862.38 | Research |
| Study: ISB 1442-101 | ||||||
| 08/19/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $4,746.00 | General |
| Category: Oncology | ||||||
| 06/02/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $106.24 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,977.00 | General |
| 05/17/2024 | IGI Inc | — | — | Cash or cash equivalent | $2,560.15 | Research |
| Study: ISB 1442-101 | ||||||
| 05/17/2024 | IGI Inc | — | — | Cash or cash equivalent | $2,189.65 | Research |
| Study: ISB 1442-101 | ||||||
| 05/17/2024 | IGI Inc | — | — | Cash or cash equivalent | $2,189.65 | Research |
| Study: ISB 1442-101 | ||||||
| 05/17/2024 | IGI Inc | — | — | Cash or cash equivalent | $1,720.35 | Research |
| Study: ISB 1442-101 | ||||||
| 05/17/2024 | IGI Inc | — | — | Cash or cash equivalent | $864.50 | Research |
| Study: ISB 1442-101 | ||||||
| 05/13/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 03/22/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $211.36 | General |
| Category: Oncology | ||||||
| 03/11/2024 | IGI Inc | — | — | Cash or cash equivalent | $6,916.00 | Research |
| Study: ISB 1442-101 | ||||||
| 03/11/2024 | IGI Inc | — | — | Cash or cash equivalent | $3,208.53 | Research |
| Study: ISB 1442-101 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ISB 1442-101 | IGI Inc | $24,096 | 10 |
| CADPT07A12101 | Novartis Pharmaceuticals Corporation | $609.30 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 249 | 622 | $329,289 | $69,527 |
| 2022 | 6 | 267 | 443 | $238,237 | $51,439 |
| 2021 | 4 | 166 | 428 | $223,154 | $52,119 |
| 2020 | 5 | 116 | 339 | $154,042 | $33,743 |
Total Patients
798
Total Services
1,832
Medicare Billing
$206,827
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 122 | 305 | $171,940 | $35,921 | 20.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 28 | 213 | $89,514 | $21,673 | 24.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 38 | 38 | $29,546 | $5,018 | 17.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 25 | $23,258 | $3,706 | 15.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 11 | 14 | $4,756 | $1,149 | 24.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 14 | 16 | $5,564 | $1,080 | 19.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 11 | 11 | $4,711 | $980.30 | 20.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 96 | 222 | $119,251 | $26,536 | 22.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 47 | 47 | $35,230 | $7,516 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 52 | 81 | $27,272 | $6,748 | 24.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 37 | 37 | $36,019 | $6,258 | 17.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 30 | $12,188 | $2,436 | 20.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 20 | 26 | $8,277 | $1,943 | 23.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 89 | 265 | $138,224 | $33,653 | 24.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 109 | $42,436 | $9,458 | 22.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 33 | 33 | $23,891 | $5,369 | 22.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 21 | $18,603 | $3,638 | 19.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 23 | 179 | $67,841 | $16,325 | 24.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 53 | 119 | $60,467 | $11,662 | 19.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 17 | 17 | $12,019 | $2,550 | 21.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 12 | $9,059 | $2,134 | 23.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 12 | 12 | $4,656 | $1,073 | 23.0% |
About Benjamin Derman
Benjamin Derman is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2013. The National Provider Identifier (NPI) number assigned to this provider is 1730526310.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Benjamin Derman has received a total of $62,809 in payments from pharmaceutical and medical device companies, with $35,768 received in 2024. These payments were reported across 54 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($36,755).
As a Medicare-enrolled provider, Derman has provided services to 798 Medicare beneficiaries, totaling 1,832 services with total Medicare billing of $206,827. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 05/23/2013
- Last Updated 10/24/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1730526310
Products in Payments
- SARCLISA (Biological) $17,717
- DARZALEX (Biological) $7,631
- DARZALEX (Drug) $2,725
- CARVYKTI (Drug) $1,530
- clonoSEQ (Device) $772.87
- TALVEY (Biological) $550.00
- XPOVIO (Drug) $211.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678